Wan mɛrɛsin fɔ kansa wit wi yon bɔdi? Wetin yu nid fɔ no bɔt imyunotɛrapi

We wi yɛri di wɔd “kansa,” fred ɛn wɔri kin kam na wi maynd. Dat na nɔmal tin. Bɔt we di sayɛns bɔt mɛrɛsin dɔn go bifo, di we aw dɛn de mɛn kansa dɔn bɛtɛ pasmak. Tide, a go tɔk to una bɔt wan fayn fayn tritmɛnt we dɔn chenj di gem na di fɛt agens kansa ɛn briŋ nyu op to bɔku pipul dɛn. Dɛn kɔl dis Immunotherapy. Fɔ tɔk am simpul wan, instead fɔ gi ɔda mɛrɛsin fɔ fɛt kansa , wi kin yuz wi yon difens fɔ fɛt am. Lɛ wi si aw dis kin wok.

So, wetin na Immunotherapy?

Fɔ ɔndastand dis, lɛ wi tek wan smɔl ɛgzampul. If yu gɛt alɛji , lɛk fɔ dɔst mit, yu kin dɔn gɛt alɛji shot. Di shot dɛn gɛt smɔl smɔl tin we de mek pɔsin gɛt alɛrjen. We i go insay yu bɔdi, yu imyun sistɛm kin bigin fɔ wok agens am, bɔt i nɔ go mek yu sik. As yu de inkrisayz di doz smɔl smɔl, yu bɔdi kin yus to di alɛrgen. Dat min se yu bɔdi de bil wan imyuniti fɔ am.

Immunotherapy na sɔntin lɛk dat. Kansa na we wan pan wi yon sɛl dɛn bigin fɔ biev “bad” we wi nɔ ebul fɔ kɔntrol am. Di op fɔ imyunotɛrapi tritmɛnt na fɔ ɛp wi bɔdi in natura difɛns sistɛm fɔ no dɛn “bad sɛl” ya ɛn tren insɛf fɔ pwɛl dɛn. Jɔs lɛk aw wi de fɛt wan vayrɔs ɔ baktri we de kam insay wi bɔdi.

Wetin na di men kayn imyunotɛrapi?

Risach pipul dɛn dɔn fɛn bɔku we dɛn we wi imyun sistɛm kin no ɛn pwɛl di kansa sɛl dɛn. Lɛ wi tek tɛm luk sɔm pan di men kayn dɛn.

1. Adoptiv T-Sɛl Imyunotɛrapi (Spɛshal tren T-sɛl tɛrapi) .

Dis tan lɛk fɔ tren spɛshal fɔs dɛn. Wan pan di men sojaman dɛn we de na wi imyun sistɛm na T-sɛl .

Insay dis tritmɛnt, dɔktɔ dɛn kin tek sɔm pan dɛn T-sɛl ya frɔm yu tumbu. Dɔn, na di lab, dɛn kin luk fɔ uswan pan dɛn T-sɛl ya we de fɛt di kansa mɔ. Dɛn kin pik di “best sojaman dɛn,” dɛn kin mek dɛn jɛnɛtiks, mek dɛn strɔng mɔ ɛn mɔ, ɛn mek dɛn gro to bɔku bɔku pipul dɛn.

Fɔ dɔn, dɛn kin put dis “super-powered T-cell army” bak insay yu bɔdi tru wan IV. Naw dɛn sɛl ya kin go stret fɔ fɛn ɛn pwɛl di kansa sɛl dɛn.

Wan pan di tritmɛnt dɛn we pipul dɛn lɛk pas ɔl ɔnda dis kategori na CAR T-cell therapy . Dɛn kin yuz am fɔ pikin ɛn big pipul dɛn we gɛt lukimiya ɛn sɔm kayn kansa, lɛk limfoma, we nɔ dɔn ansa ɔda tritmɛnt dɛn.

2. Chɛkpoint Inhibitɔ dɛn

Wi imyun sistɛm gɛt bak wan sistɛm we de mek “brɛk.” Dɛn kɔl dɛn tin ya chɛk-point. Dɛn brek ya de fɔ stɔp wi imyun sistɛm fɔ atak wi yon wɛlbɔdi sɛl dɛn we nɔ nid fɔ apin.

Bɔt kɔni kɔni kansa sɛl dɛn kin tek advantej pan dis brek sistɛm. dεn de mek protin dεm na dεn sεf we de aktibכt dεn chεkpכynt dεm ya, we de sεnd signal to di difεns sistεm, se, "Mi na wan pan yu, nכ atak mi." I tan lɛk se tifman de wɛr polis yunifom.

di chεkpכynt inhibito dεm de wok bay we dεn de rilis dis "brek" we de ol di kεnsar sεl dεm na in ples. Dis kin mek wi T-sɛl dɛn no se kansa na ɛnimi ɛn atak am.

Dis tritmɛnt we dɛn kin yuz naw fayn fayn wan fɔ bɔku kayn kansa, lɛk kansa na di lɔng, bɔdi, kidni, ɛn skin (melanoma).

3. Mɔnoklɔnal Antibodi dɛn

Dis na antibodies, we dɛn mek spɛshal wan na lab. Dɛn tan lɛk "mishɔl" we kin fɛn ɛn kech kansa sɛl dɛn.

wi imyun sistεm nכ kin ebul fכ no כltεm di kεnsar sεl dεm as "bad." Monoclonal antibodies de ɛp am fɔ du dat. Dɛn antibodi dɛn ya kin stik na di say we di kansa sɛl dɛn de. Dɔn, i tan lɛk se flag de flay oba da sɛl de, we de mek am izi fɔ di imyun sistɛm fɔ si am. I tan lɛk se yu se, "Na di ɛnimi ya." Dɔn di T-sɛl dɛn kin ebul fɔ pwɛl dɛn kansa sɛl dɛn de izi wan.

Sɔm monoklɔnal antibodi dɛn gɛt anti-kansa drɔgs ( kemotɛrapi ) ɔ redioaktiv tin dɛn we dɛn tay pan dɛn. Dɔn dis antibodi kin kɛr di mɛrɛsin go dairekt to di kansa sɛl ɛn kɛr am go.

4. Kansa Vaysin dɛn

Dɛn tin ya jɔs tan lɛk di vaysin dɛn we dɛn kin gi ɔltɛm. Tu men kayn dɛn de:

• Vaysin wae de mek pɔrsin nɔr gɛt dis sik: Dis na vaysin wae de protɛkt frɔm vayrɔs dɛm wae kin mek yu gɛt kansa. Di bɛst ɛgzampul na di HPV (Human Papillomavirus) vaysin. Dis HPV vayrɔs kin mek yu gɛt kansa na yu sɛvikal ɛn bak sɔm ɔda kayn kansa. Fɔ gɛt di HPV vaysin kin ridyus da risk de bad bad wan. I rili impɔtant fɔ tɔk to yu dɔktɔ bɔt dis ɛn no mɔ.
• Tritmɛnt vaysin: Dɛn mek dɛn tin ya fɔ tren di imyun sistɛm fɔ atak wan kansa we dɔn ɔlrɛdi de na di bɔdi.

Wetin na di fiuja fɔ imyunotɛrapi?

Immunotherapy stil na wan tin we de divɛlɔp kwik kwik wan, bikɔs sayɛnsman dɛn de tray ɔltɛm fɔ ɔndastand mɔ bɔt aw wi imyun sistɛm de fɛt kansa.

Apat frɔm dat, dɛn de du risach fɔ si if dɛn kin gi imyunotɛrapi wit ɔda tritmɛnt dɛn lɛk kemotɛrapi fɔ mek di tin dɛn we de apin bɛtɛ. Sɔntɛnde, dɛn kin gi tu kayn imyunotɛrapi togɛda.

Bɔt wan big kwɛstyɔn stil de we dɛn nɔ gɛt ansa. Dat na, wae mek dis tritmɛnt, lɛk ɔda tritmɛnt, kin woke fayn fɔ sɔm sik pipul dɛm wae nɔr kin woke fayn fɔ ɔda pipul dɛm. Risach stil de go bifo fɔ no di rizin dɛn fɔ dis.

Imyunotɛrapi, kansa tritmɛnt, kansa tritmɛnt sinhala , T-sɛl, chɛkpɔynt inhibito, monoklɔnal antibodi, CAR T-sɛl tɛrapi, kansa, Sri Lanka